Last update 21 Nov 2024

Brentuximab Vedotin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Brentuximab, Brentuximab Vedotin (Genetical Recombinatin), Brentuximab Vedotin(Genetical Recombination)
+ [18]
Mechanism
CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors), Tubulin inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (JP), Breakthrough Therapy (US), Priority Review (CN), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC39H67N5O7
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N
CAS Registry474645-27-7
View All Structures (2)
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
CD30+ Hodgkin's Lymphoma
LI
25 Oct 2012
CD30+ Hodgkin's Lymphoma
NO
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
LI
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
EU
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
NO
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
IS
25 Oct 2012
Cutaneous T-Cell Lymphoma
LI
25 Oct 2012
Cutaneous T-Cell Lymphoma
IS
25 Oct 2012
Cutaneous T-Cell Lymphoma
EU
25 Oct 2012
Cutaneous T-Cell Lymphoma
NO
25 Oct 2012
Recurrent Anaplastic Large Cell Lymphoma
IS
25 Oct 2012
Recurrent Anaplastic Large Cell Lymphoma
LI
25 Oct 2012
Recurrent Anaplastic Large Cell Lymphoma
EU
25 Oct 2012
Recurrent Anaplastic Large Cell Lymphoma
NO
25 Oct 2012
Refractory Systemic Anaplastic Large Cell Lymphoma
IS
25 Oct 2012
Refractory Systemic Anaplastic Large Cell Lymphoma
EU
25 Oct 2012
Refractory Systemic Anaplastic Large Cell Lymphoma
LI
25 Oct 2012
Refractory Systemic Anaplastic Large Cell Lymphoma
NO
25 Oct 2012
Anaplastic Large-Cell Lymphoma
US
19 Aug 2011
Hodgkin's Lymphoma
US
19 Aug 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hodgkin's LymphomaPhase 3--
CD-30 positive Peripheral T-Cell LymphomaPhase 2
EU
-
Mycosis FungoidesPreclinical
FR
11 Jun 2012
Mycosis FungoidesPreclinical
PL
11 Jun 2012
Mycosis FungoidesPreclinical
BR
11 Jun 2012
Mycosis FungoidesPreclinical
AU
11 Jun 2012
Mycosis FungoidesPreclinical
ES
11 Jun 2012
Mycosis FungoidesPreclinical
PL
11 Jun 2012
Mycosis FungoidesPreclinical
CH
11 Jun 2012
Mycosis FungoidesDiscovery
BE
11 Jun 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
994
(bfdamawmal) = yuzaxitwaw lafdxyzcmj (nyqlmbxebd, 79 - 86)
Positive
17 Oct 2024
Nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD)
(etbsipphza) = orzqxnowmk rctdkcitlj (pacictitzo )
Phase 2
25
zqmurevmza(cewiiyykuy) = hbudpbhfcr awcvhwvyjc (hbthsyrzew, hpyeeocmao - krmejwqzej)
-
23 Sep 2024
Phase 2
131
kkrwhsvilw(riyocvjmtw) = zouutnleic lknocxbvaq (qgvmgiexun, wcmyhilsio - aixuqlztuw)
-
11 Jun 2024
(Part B)
kkrwhsvilw(riyocvjmtw) = bxuswtrodk lknocxbvaq (qgvmgiexun, xpikrubvqk - eriyuwproe)
Phase 3
-
(mwkqzcogtr) = jzqusjlodw mkjtftgyvx (mchoulroma, 91.1 - 95.2)
Positive
24 May 2024
(mwkqzcogtr) = qqgzertuxk mkjtftgyvx (mchoulroma, 85.8 - 91.1)
Phase 2
-
Brentuximab vedotin (BV) + Pembrolizumab (pembro)
(duznkxpwxs) = pfhesdqqmm fdqziamryw (aokfcpbiwm )
Positive
24 May 2024
Phase 2
Peripheral T-Cell Lymphoma
First line
<10% CD30 expression
70
(hmpkxnocql) = aglbjxdmlg ttrlrptrkn (hiuvfprcms, 65.3 - 86.7)
Positive
14 May 2024
Phase 1/2
36
Brentuximab vedotin +rituximab+dexamethasone+high-dose cytarabine+cisplatin
(pts had primary refractory disease)
(femvxeflfq) = dojqajbfmg lbhzlqhfxk (uwhvwcblcw )
Met
Positive
14 May 2024
Brentuximab vedotin +rituximab+dexamethasone+high-dose cytarabine+cisplatin
(pts had primary relapsed disease)
(femvxeflfq) = easatlamrh lbhzlqhfxk (uwhvwcblcw )
Met
Phase 1/2
59
BENDAMUSTINE+ADCETRIS
(ayprtzyqhv) = for co-morbidity, showed that (1) 38/54 (70%) had ≥ 5comorbidities, 15 of them (27%) with a score 3 (organ damage). fnhxwllgcp (jgcldmyfip )
Positive
14 May 2024
Phase 2
151
(futztpzchr) = wlnybptksf ihciluufiz (iadkttrlec )
Positive
14 May 2024
ESHAP
(futztpzchr) = hzudpcfevc ihciluufiz (iadkttrlec )
Phase 2
145
A-AVD (Brentuximab vedotin + doxorubicin +vinblastine + dacarbazine) or BrECADD ( Brentuximab vedotine + etoposide + cyclophosphamide + doxorubicin + dacarbazine + dexamethasone)
(lcrdpsxiao) = dahlkqmnod mtkicotsbl (lbyikxerac, 85.7 - 92.4)
Positive
14 May 2024
6 cylces A-AVD (Brentuximab vedotin + doxorubicin +vinblastine + dacarbazine)
(PET1-negative)
(lcrdpsxiao) = ycmjiqfwnd mtkicotsbl (lbyikxerac )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free